REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Advagene Biopharma Co., Ltd. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Advagene Biopharma Co., Ltd. Profile Updated: July 06, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Advagene Biopharma Co., Ltd. is mainly engaged in the development of nasal spray-type influenza vaccines, respiratory allergic treatment vaccines, and other vaccine applications. The company was founded in 2006 and is headquartered in Taipei City, Taiwan.

Headquarters
6F,No 308, Sec.1,Neihu Rd, Niehu Dist
Taipei City; Taipei City;

Contact Details: Purchase the Advagene Biopharma Co., Ltd. report to view the information.

Website: http://www.advagene.com.tw

Basic Information
Total Employees:
Purchase the Advagene Biopharma Co., Ltd. report to view the information.
Outstanding Shares:
Purchase the Advagene Biopharma Co., Ltd. report to view the information.
Financial Auditors:
Purchase the Advagene Biopharma Co., Ltd. report to view the information.
Incorporation Date:
September 19, 2006
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
25.42%
Purchase this report to view the information.
4.79%
Purchase this report to view the information.
4.22%
Purchase this report to view the information.
2.58%
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Advagene Biopharma Co., Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
32.22%▲
EBITDA
22.71%▲
Net Profit (Loss) for the Period
32.64%▲
Total assets
34.72%▲
Total equity
27.51%▲
Return on Equity (ROE)
25.84%▲
Quick Ratio
0.17%▲
Cash Ratio
1.67%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo